Status:
COMPLETED
Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions
Lead Sponsor:
Sandoz
Conditions:
Chronic Hepatitis C
Eligibility:
FEMALE
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under fasting conditions.
Eligibility Criteria
Inclusion
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2001
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00960479
Start Date
January 1 2001
End Date
February 1 2001
Last Update
March 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.